The Multiple Myeloma Therapy Market is gaining momentum as pharmaceutical companies develop more advanced treatments for this plasma-cell cancer. WiseGuyReports estimates that the global market reached USD 37.4 billion in 2024, increased to USD 39.8 billion in 2025, and could grow to approximately USD 75.0 billion by 2035, representing a 6.5% CAGR during 2026–2035.

A key change in the market is the growing importance of targeted and immune-based therapies. The main therapy categories include chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. Targeted therapy is a particularly important segment, with its market value expected to increase from USD 15.0 billion in 2024 to USD 30.0 billion by 2035 as researchers continue to develop treatments that address specific biological mechanisms associated with multiple myeloma.

The market is also segmented by treatment stage, covering initial treatment, relapsed treatment, and maintenance therapy. Maintenance treatment is important for extending disease control after initial response, while relapsed treatment creates demand for newer therapies when patients develop resistance to earlier treatments. Oral, intravenous, and subcutaneous delivery options further broaden the treatment landscape.

North America remains the largest regional market, supported by advanced healthcare infrastructure, high healthcare expenditure, strong pharmaceutical research activity, and access to innovative therapies. The region was valued at around USD 17.2 billion in 2024 and is projected to reach USD 32.5 billion by 2035. Asia Pacific is also attracting attention because improving healthcare systems and greater awareness are expanding access to multiple myeloma treatments.

Looking ahead, CAR-T therapies, monoclonal antibodies, BCMA-targeted treatments, and personalized medicine are expected to remain important areas of development. Collaborations between pharmaceutical and biotechnology companies are also supporting new product pipelines and manufacturing capacity. These advances could expand treatment choices while creating new opportunities across drug development, clinical research, and specialized cancer care.